These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11931978)

  • 1. Being partial to psychostimulant addiction therapy.
    Pulvirenti L; Koob GF
    Trends Pharmacol Sci; 2002 Apr; 23(4):151-3. PubMed ID: 11931978
    [No Abstract]   [Full Text] [Related]  

  • 2. A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry.
    Gold MS; Badgaiyan RD; Blum K
    Psychiatr Clin North Am; 2015 Sep; 38(3):419-62. PubMed ID: 26300032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.
    Blum K; Chen TJ; Morse S; Giordano J; Chen AL; Thompson J; Allen C; Smolen A; Lubar J; Stice E; Downs BW; Waite RL; Madigan MA; Kerner M; Fornari F; Braverman ER
    Postgrad Med; 2010 Nov; 122(6):214-26. PubMed ID: 21084796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor agonists, partial agonists and psychostimulant addiction.
    Pulvirenti L; Koob GF
    Trends Pharmacol Sci; 1994 Oct; 15(10):374-9. PubMed ID: 7809953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pharmacological approaches to drug abuse treatment.
    Edens E; Massa A; Petrakis I
    Curr Top Behav Neurosci; 2010; 3():343-86. PubMed ID: 21161760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.
    Blum K; Gold MS
    Med Hypotheses; 2011 Apr; 76(4):576-84. PubMed ID: 21306831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The neurobiology of psychostimulant addiction].
    Fernández-Espejo E
    Rev Neurol; 2006 Aug 1-15; 43(3):147-54. PubMed ID: 16871480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurobehavioral Sequelae of Psychostimulant Abuse.
    Djamshidian A
    Int Rev Neurobiol; 2015; 120():161-77. PubMed ID: 26070757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
    Keck TM; John WS; Czoty PW; Nader MA; Newman AH
    J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addiction therapeutics: obstacles and opportunities.
    Skolnick P; Volkow ND
    Biol Psychiatry; 2012 Dec; 72(11):890-1. PubMed ID: 23121867
    [No Abstract]   [Full Text] [Related]  

  • 11. [Assessment of addiction to psychotropic medications].
    Bischof G; John U; Rumpf HJ
    Dtsch Med Wochenschr; 2009 Nov; 134(47):2397-8. PubMed ID: 19911329
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug Therapy.
    He RH; Tao R
    Adv Exp Med Biol; 2017; 1010():219-245. PubMed ID: 29098675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rebalancing the Addicted Brain: Oxytocin Interference with the Neural Substrates of Addiction.
    Bowen MT; Neumann ID
    Trends Neurosci; 2017 Dec; 40(12):691-708. PubMed ID: 29128108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro- and anti-addictive neurotrophic factors and cytokines in psychostimulant addiction: mini review.
    Yamada K; Nabeshima T
    Ann N Y Acad Sci; 2004 Oct; 1025():198-204. PubMed ID: 15542718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to special issue "addiction pharmacotherapy and special populations".
    McCance-Katz EF
    Subst Use Misuse; 2005; 40(13-14):1895-7. PubMed ID: 16282084
    [No Abstract]   [Full Text] [Related]  

  • 16. Health for life. Addiction: how to break the chain.
    Miller MC
    Newsweek; 2005 Dec; 146(24):58. PubMed ID: 16375164
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of impulsivity in psychostimulant- and stress-induced dopamine release: Review of human imaging studies.
    Bosker WM; Neuner I; Shah NJ
    Neurosci Biobehav Rev; 2017 Jul; 78():82-90. PubMed ID: 28438467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole treatment for cocaine cravings.
    Rosenbaum JF; Fredman SJ
    Am J Psychiatry; 1999 Nov; 156(11):1834. PubMed ID: 10553755
    [No Abstract]   [Full Text] [Related]  

  • 19. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
    Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
    Bergman J
    Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.